These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 12737534)

  • 1. Transdermal drug delivery system of haloperidol to overcome self-induced extrapyramidal syndrome.
    Samanta MK; Dube R; Suresh B
    Drug Dev Ind Pharm; 2003 Apr; 29(4):405-15. PubMed ID: 12737534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Penetration enhancer-containing spanlastics (PECSs) for transdermal delivery of haloperidol: in vitro characterization, ex vivo permeation and in vivo biodistribution studies.
    Fahmy AM; El-Setouhy DA; Ibrahim AB; Habib BA; Tayel SA; Bayoumi NA
    Drug Deliv; 2018 Nov; 25(1):12-22. PubMed ID: 29219628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of Transdermal Delivery of Haloperidol via Spanlastic Dispersions: Entrapment Efficiency vs. Particle Size.
    Fahmy AM; El-Setouhy DA; Habib BA; Tayel SA
    AAPS PharmSciTech; 2019 Jan; 20(3):95. PubMed ID: 30694404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
    Tada M; Shirakawa K; Matsuoka N; Mutoh S
    Psychopharmacology (Berl); 2004 Oct; 176(1):94-100. PubMed ID: 15083255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transdermal delivery enhancement of haloperidol from gel formulations by 1,8-cineole.
    Elgorashi AS; Heard CM; Niazy EM; Noureldin OH; Pugh WJ
    J Pharm Pharmacol; 2008 Jun; 60(6):689-92. PubMed ID: 18498703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quetiapine : A Review of its Use in Schizophrenia.
    Gunasekara NS; Spencer CM
    CNS Drugs; 1998 Apr; 9(4):325-40. PubMed ID: 27521016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients.
    Hesslinger B; Normann C; Langosch JM; Klose P; Berger M; Walden J
    J Clin Psychopharmacol; 1999 Aug; 19(4):310-5. PubMed ID: 10440457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formulation, in vitro, and in vivo evaluation of matrix-type transdermal patches containing olanzapine.
    Aggarwal G; Dhawan S; Harikumar SL
    Pharm Dev Technol; 2013; 18(4):916-25. PubMed ID: 21913873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aripiprazole: new drug. Just another neuroleptic.
    Prescrire Int; 2005 Oct; 14(79):163-7. PubMed ID: 16285069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial.
    Heck AH; Haffmans PM; de Groot IW; Hoencamp E
    Schizophr Res; 2000 Dec; 46(2-3):97-105. PubMed ID: 11120421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.
    Tran PV; Dellva MA; Tollefson GD; Beasley CM; Potvin JH; Kiesler GM
    J Clin Psychiatry; 1997 May; 58(5):205-11. PubMed ID: 9184614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of d-limonene, alpha-pinene and cineole on in vitro transdermal human skin penetration of chlorpromazine and haloperidol.
    Almirall M; Montaña J; Escribano E; Obach R; Berrozpe JD
    Arzneimittelforschung; 1996 Jul; 46(7):676-80. PubMed ID: 8842336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia.
    Reschke RW
    Dis Nerv Syst; 1974 Mar; 35(3):112-5. PubMed ID: 17894080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine.
    Potkin SG; Thyrum PT; Alva G; Bera R; Yeh C; Arvanitis LA
    J Clin Psychopharmacol; 2002 Apr; 22(2):121-30. PubMed ID: 11910256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An investigation of ethnic and gender differences in the pharmacodynamics of haloperidol.
    Zhang-Wong J; Beiser M; Zipursky RB; Bean G
    Psychiatry Res; 1998 Dec; 81(3):333-9. PubMed ID: 9925184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Asymptomatic QTc prolongation during coadministration of aripiprazole and haloperidol.
    Leo R; Razzini C; Di Lorenzo G; Bianchi F; Tesauro M; Zanasi M; Siracusano A; Romeo F
    J Clin Psychiatry; 2008 Feb; 69(2):327-8. PubMed ID: 18363460
    [No Abstract]   [Full Text] [Related]  

  • 19. Dose-dependent reduced haloperidol/haloperidol ratios: influence of patient-related variables.
    Lane HY; Chang WH; Chang YC; Hu OY; Lin HN; Jann MW; Hu WH
    Psychiatry Res; 1997 Sep; 72(2):127-32. PubMed ID: 9335203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between negative symptoms of schizophrenia and extrapyramidal side effects with haloperidol and olanzapine.
    Allan ER; Sison CE; Alpert M; Connolly B; Crichton J
    Psychopharmacol Bull; 1998; 34(1):71-4. PubMed ID: 9564201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.